Login to Your Account



Actelion Shares Fall on Clazosentan Phase III Miss

By Cormac Sheridan


Wednesday, September 29, 2010
Shares in Actelion Pharmaceuticals Ltd. dropped by almost 8 percent Monday on news that clazosentan failed to reach the primary endpoint in a Phase III pivotal trial in patients who had undergone surgical clipping to treat a form of stroke called aneurysmal subarachnoid hemorrhage (aSAH). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription